Core Insights - BrightSpring Health Services, Inc. (BTSG) is positioned to potentially continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates by an average of 76.64% in the last two quarters [1][2]. Earnings Performance - For the last reported quarter, BrightSpring Health Services, Inc. achieved earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.19 per share, resulting in a surprise of 15.79% [2]. - In the previous quarter, the company was expected to post earnings of $0.08 per share but delivered $0.19 per share, leading to a significant surprise of 137.50% [2]. Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for BrightSpring Health Services, Inc., with a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of an earnings beat [5][8]. - The current Earnings ESP for BrightSpring Health Services, Inc. is +49.89%, suggesting that analysts have recently become more optimistic about the company's earnings prospects [8]. Zacks Rank and Success Rate - The combination of a positive Earnings ESP and a Zacks Rank 3 (Hold) suggests that the company is likely to beat earnings estimates, with historical data indicating that such combinations result in positive surprises nearly 70% of the time [6][8].

Group 1 - Medpace (MEDP) has returned 59.8% year-to-date, significantly outperforming the Medical sector, which has gained about 1.8% on average [4] - Medpace holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook with a consensus estimate for full-year earnings moving 10.4% higher in the past quarter [3] - The Medical Services industry, to which Medpace belongs, has lost an average of 0.3% so far this year, further highlighting Medpace's strong performance [5] Group 2 - Black Diamond (BDTX) is another Medical stock that has outperformed the sector with a year-to-date return of 86.5% and holds a Zacks Rank of 1 (Strong Buy) [4][5] - The Medical - Biomedical and Genetics industry, which includes Black Diamond, has gained 8.7% year-to-date and is currently ranked 96 [6] - Investors interested in Medical stocks should closely monitor both Medpace and Black Diamond for continued strong performance [6]

Core Insights - Organon (OGN) shares closed at $10.84, reflecting a decline of 1.54% from the previous trading session, underperforming the S&P 500's gain of 0.37% [1] - Over the past month, Organon shares have increased by 6.07%, surpassing the Medical sector's gain of 5.9% and the S&P 500's gain of 4.26% [1] Earnings Performance - The upcoming earnings per share (EPS) for Organon is projected at $0.93, indicating a 6.90% increase compared to the same quarter last year [2] - Quarterly revenue is estimated at $1.57 billion, which represents a decrease of 0.63% from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are expected to be $3.81 per share, with revenue projected at $6.3 billion, reflecting changes of -7.3% and -1.59% respectively from the prior year [3] - Recent adjustments to analyst estimates suggest a favorable outlook on Organon's business health and profitability [3] Valuation Metrics - Organon has a Forward P/E ratio of 2.89, which is significantly lower than the industry average Forward P/E of 17.42, indicating a valuation discount [5] - The company also has a PEG ratio of 0.96, compared to the Medical Services industry's average PEG ratio of 1.66 [6] Industry Context - The Medical Services industry, which includes Organon, holds a Zacks Industry Rank of 143, placing it in the bottom 43% of over 250 industries [6] - The strength of individual industry groups is measured by the Zacks Industry Rank, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, capitalizing on established price movements [1] Company Overview: Alignment Healthcare (ALHC) - ALHC currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance [3] Price Performance - Over the past week, ALHC shares increased by 5.99%, while the Zacks Medical Services industry declined by 0.74% [5] - In a longer timeframe, ALHC shares rose by 24.31% over the past quarter and 52.2% over the last year, outperforming the S&P 500, which increased by 7.36% and 19.22% respectively [6] Trading Volume - ALHC's average 20-day trading volume is 4,794,561 shares, indicating a bullish sentiment as rising stocks with above-average volume are generally seen as positive [7] Earnings Outlook - In the last two months, one earnings estimate for ALHC has increased, while none have decreased, raising the consensus estimate from -$0.21 to -$0.18 [9] - For the next fiscal year, two estimates have moved upwards with no downward revisions, indicating positive earnings momentum [9] Conclusion - Given the strong price performance, positive earnings outlook, and high momentum score, ALHC is recommended as a solid pick for investors seeking growth opportunities [11]

Core Viewpoint - Pediatrix Medical Group (MD) has shown strong stock performance, with a 33.4% increase since the beginning of the year, outperforming the Zacks Medical sector and Zacks Medical Services industry [1][2] Financial Performance - The company has consistently beaten earnings estimates, reporting an EPS of $0.53 against a consensus estimate of $0.42 in its last earnings report [2] - For the current fiscal year, Pediatrix is expected to post earnings of $1.78 per share on revenues of $1.89 billion, reflecting a 17.88% increase in EPS but a 6.3% decrease in revenues [3] - The next fiscal year projections indicate earnings of $1.80 per share on revenues of $1.94 billion, showing a year-over-year change of 1.12% in EPS and 2.63% in revenues [3] Valuation Metrics - Pediatrix Medical Group has a Value Score of A, a Growth Score of A, and a Momentum Score of F, resulting in a combined VGM Score of A [6] - The stock trades at 9.8X current fiscal year EPS estimates, significantly lower than the peer industry average of 17.4X, indicating strong value potential [7] - On a trailing cash flow basis, the stock trades at 9.9X compared to the peer group's average of 10.2X, positioning it favorably for value investors [7] Zacks Rank - The company holds a Zacks Rank of 1 (Strong Buy), driven by rising earnings estimates, making it an attractive option for investors [8][9] Industry Comparison - Compared to industry peers, Charles River Laboratories International, Inc. (CRL) also shows strong performance with a Zacks Rank of 2 (Buy) and solid earnings expectations [10][11] - CRL is expected to post earnings of $10.11 per share on revenues of $3.97 billion for the current fiscal year, with shares gaining 8.1% over the past month [11][12]

Core Insights - The article compares two Medical Services stocks, Solventum (SOLV) and Medpace (MEDP), to determine which offers better value for investors [1] Valuation Metrics - Solventum has a Zacks Rank of 1 (Strong Buy), indicating a stronger earnings outlook compared to Medpace, which has a Zacks Rank of 3 (Hold) [3] - SOLV's forward P/E ratio is 12.56, significantly lower than MEDP's forward P/E of 38.33, suggesting SOLV is more attractively priced [5] - The PEG ratio for SOLV is 3.03, while MEDP's PEG ratio is 3.37, indicating SOLV may offer better value relative to its expected earnings growth [5] - SOLV's P/B ratio is 3.54, compared to MEDP's P/B of 87.39, further highlighting SOLV's relative valuation advantage [6] - Based on these metrics, SOLV holds a Value grade of B, while MEDP has a Value grade of D, indicating a stronger value proposition for SOLV [6] Earnings Outlook - SOLV is noted for its improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, positioning it as the superior value option at present [7]

Company Performance - Medpace (MEDP) closed at $536.17, down 1.42% from the previous session, underperforming the S&P 500's gain of 0.06% [1] - Over the past month, Medpace shares have increased by 13.02%, outperforming the Medical sector's gain of 5.06% and the S&P 500's gain of 3.94% [1] Upcoming Earnings - Medpace is set to release its earnings report on October 22, 2025, with an expected EPS of $3.49, reflecting a 15.95% increase from the same quarter last year [2] - The Zacks Consensus Estimate projects revenue of $640.76 million, up 20.14% from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $13.99 per share, indicating a 10.77% increase, while revenue is projected at $2.46 billion, showing a 16.83% increase from the prior year [3] Analyst Estimates - Recent changes in analyst estimates for Medpace are important as they indicate shifts in near-term business trends, with positive changes reflecting analyst optimism [3][4] Zacks Rank and Valuation - Medpace currently holds a Zacks Rank of 3 (Hold), with the Zacks Rank system historically outperforming, particularly stocks rated 1 [5] - The Forward P/E ratio for Medpace is 38.88, significantly higher than the industry average of 17.12, and the PEG ratio stands at 3.42 compared to the industry average of 1.64 [6] Industry Overview - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 135, placing it in the bottom 46% of all industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Group 1 - Cardinal Health (CAH) stock received a Relative Strength (RS) Rating upgrade from 66 to 71, indicating an improvement in share price performance but still below the desired threshold of 80 [1] - Cencora has shown improved technical performance with a Relative Strength Rating upgrade, reaching a score of 86, although it remains shy of key thresholds [3] - Cencora reported $81.5 billion in sales last quarter, marking a significant performance in a challenging market environment [3] Group 2 - The market is currently influenced by tariff wars, which have led to sellers dominating the trading environment [3] - Cencora has been recognized as a new addition to the Big Cap 20, reflecting its rising prominence in the market [3] - The stock lists from Investor's Business Daily (IBD) include notable names such as Mueller Water and Netflix, indicating a diverse range of investment opportunities [3]

Core Viewpoint - Organon is experiencing a mixed performance in the market, with a recent decline in stock price despite a notable gain over the past month, and upcoming earnings expectations indicating slight growth in earnings but a decrease in revenue [1][2][3]. Group 1: Stock Performance - Organon closed at $10.12, reflecting a -2.79% change from the previous day, underperforming compared to the S&P 500's loss of 0.5% [1]. - Over the past month, Organon shares have increased by 13.15%, while the Medical sector has decreased by 0.7% and the S&P 500 has gained 2.74% [1]. Group 2: Earnings Expectations - Analysts anticipate Organon will report earnings of $0.93 per share, representing a year-over-year growth of 6.9% [2]. - The Zacks Consensus Estimate for revenue is projected at $1.57 billion, which is a decline of 0.63% compared to the previous year [2]. - For the full year, earnings are expected to be $3.81 per share and revenue at $6.3 billion, indicating changes of -7.3% and -1.59% respectively from last year [3]. Group 3: Analyst Estimates and Rankings - Recent modifications to analyst estimates for Organon reflect evolving short-term business trends, with positive revisions indicating analyst optimism [4]. - The Zacks Rank system, which assesses estimate changes, currently ranks Organon at 3 (Hold), with a 0.21% decrease in the consensus EPS estimate over the last 30 days [6]. Group 4: Valuation Metrics - Organon has a Forward P/E ratio of 2.73, significantly lower than the industry average of 16.94, indicating it is trading at a discount [7]. - The company has a PEG ratio of 0.91, compared to the industry average PEG ratio of 1.68, suggesting favorable valuation relative to projected earnings growth [7]. Group 5: Industry Context - The Medical Services industry, which includes Organon, holds a Zacks Industry Rank of 98, placing it in the top 40% of over 250 industries [8]. - Research indicates that industries in the top 50% rated by Zacks outperform those in the bottom half by a factor of 2 to 1 [8].

Core Viewpoint - Labcorp Holdings (LH) has shown strong stock performance, reaching a 52-week high and outperforming the broader medical sector and industry [1][2]. Financial Performance - Labcorp has consistently exceeded earnings expectations, reporting EPS of $4.35 against a consensus estimate of $4.14 in its last earnings report [2]. - For the current fiscal year, Labcorp is projected to achieve earnings of $16.3 per share with revenues of $14 billion, reflecting an 11.87% increase in EPS and a 7.65% increase in revenues [3]. - The next fiscal year forecasts earnings of $17.89 per share on $14.7 billion in revenues, indicating a year-over-year change of 9.74% in EPS and 4.98% in revenues [3]. Valuation Metrics - Labcorp's current trading metrics include a P/E ratio of 17.2X for the current fiscal year, which is above the peer industry average of 16.7X [7]. - The stock trades at a trailing cash flow multiple of 12.5X compared to the peer group's average of 10.1X, and has a PEG ratio of 1.79, positioning it favorably for value investors [7]. Zacks Rank and Style Scores - Labcorp holds a Zacks Rank of 2 (Buy) due to a positive earnings estimate revision trend, making it a suitable choice for investors [8]. - The company has a Value Score of A, a Growth Score of B, and a Momentum Score of F, resulting in a combined VGM Score of A [6][8]. Industry Comparison - The Medical Services industry is performing well, ranking in the top 41% of all industries, providing favorable conditions for Labcorp and its peers [11]. - Solventum Corporation (SOLV), a competitor, has a Zacks Rank of 1 (Strong Buy) and is expected to post earnings of $5.89 per share on revenues of $8.36 billion for the current fiscal year [9][10].